Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7820 in Relapsed/Refractory Myeloid Malignancies With Splicing Factor Mutations
NCT05024994Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2021
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of e7820 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2021; status: completed.
02
Drugs
e7820
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05024994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024994.